Comparative Pharmacology
Head-to-head clinical analysis: DURICEF versus ROCEPHIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURICEF versus ROCEPHIN KIT.
DURICEF vs ROCEPHIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
500 mg to 1 g orally once or twice daily.
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
None Documented
None Documented
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic